Get the Stockscreener App
3.11
4.94%
-0.13
Vaccinex Inc stock is traded at $3.11, with a volume of 412.72K.
It is down -4.94% in the last 24 hours and up +20.78% over the past month.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
See More
Previous Close:
$3.24
Open:
$3.19
24h Volume:
412.72K
Relative Volume:
4.67
Market Cap:
$8.89M
Revenue:
-
Net Income/Loss:
$-22.01M
P/E Ratio:
-0.4712
EPS:
-6.6
Net Cash Flow:
$-18.31M
1W Performance:
-18.73%
1M Performance:
+20.78%
6M Performance:
-49.09%
1Y Performance:
-76.34%
1-Day Range:
$2.93
$3.20
1-Week Range:
$2.74
$4.81
52-Week Range:
$1.39
$13.44
Vaccinex Inc Stock (VCNX) Company Profile
Name
Vaccinex Inc
Sector
Industry
Phone
585-271-2700
Address
1895 MOUNT HOPE AVE, ROCHESTER, NY
Vaccinex Inc Stock (VCNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-18 | Initiated | Ladenburg Thalmann | Buy |
Vaccinex Inc Stock (VCNX) Latest News
Vaccinex Reports Improved Immunity Correlating with - GlobeNewswire
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting - StockTitan
Vaccinex reports progress in Alzheimer's treatment study By Investing.com - Investing.com Canada
Vaccinex reports progress in Alzheimer's treatment study - Investing.com
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 - GlobeNewswire
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain - StockTitan
Vaccinex stock tanks 40% despite positive Alzheimer’s study update - MSN
Vaccinex Stock Spikes On 'Promising' Data On Alzheimer’s Drug Study: Retail Sentiment Brightens - Barchart
Vaccinex to Report Promising New Efficacy Data for - GlobeNewswire
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024 - StockTitan
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Orange Juice (OJX25) Quote - The Globe and Mail
Antibody Library Technology Market Report to 2032 -AnaptysBio Inc, MorphoSys AG, XOMA Corporation, Abzena Plc, AvantGen – IndiaPolitics.com - IndiaPolitics.com
Vaccinex faces potential Nasdaq delisting over equity shortfall - Investing.com India
BTIG Research’s latest rating for VCNX stock - Knox Daily
Vaccinex faces potential Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
Company’s Banking Shares: Up -90.42% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
Post-Trade Analysis: Vaccinex Inc (VCNX) Slides -27.92, Closing at 1.73 - The Dwinnex
Vaccinex stock hits 52-week low at $2.98 amid market challenges - Investing.com
Vaccinex stock hits 52-week low at $4.17 amid sharp annual decline - Investing.com Canada
VSME’s price-to-free cash flow ratio: What it means for investors - US Post News
Short Interest in Victory Square Technologies Inc. (OTCMKTS:VSQTF) Declines By 79.4% - Defense World
Viemed Healthcare, Inc. (NASDAQ:VMD) Shares Purchased by Victory Capital Management Inc. - Defense World
WUXI BIO Buys back ~3.32M Shrs for ~$42.55M Ytd - AASTOCKS.com
Vaxcyte Inc (PCVX) receives a Buy rating from Mizuho - Knox Daily
Victrex plc (LON:VCT) Insider Jane Toogood Acquires 508 Shares - MarketBeat
Victrex Director Buys Shares, Signals Confidence - TipRanks
Bank of New York Mellon Corp Boosts Stock Holdings in Viemed Healthcare, Inc. (NASDAQ:VMD) - Defense World
StockNews.com Initiates Coverage on Vector Group (NYSE:VGR) - Defense World
VICR Investors Have Opportunity to Lead Vicor Corporation Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
The Gross Law Firm Reminds Vicor Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 23, 2024VICR - PR Newswire
Victory Capital Management Inc. Has $496,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - Defense World
Rhumbline Advisers Has $1.01 Million Position in V2X, Inc. (NYSE:VVX) - Defense World
Choreo LLC Takes Position in Vector Group Ltd. (NYSE:VGR) - Defense World
VICOR 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Vicor CorporationVICR - Business Wire
VICR FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, - GlobeNewswire
First Eagle Investment Management LLC Purchases 2,067 Shares of V2X, Inc. (NYSE:VVX) - Defense World
Vaccinex issues new warrants, secures $6.2 million in funding - Investing.com
Victory Capital Management Inc. Cuts Stake in Wyndham Hotels & Resorts, Inc. (NYSE:WH) - Defense World
Vaccinex secures $6.2 million through warrant exercises By Investing.com - Investing.com Canada
What's Going On With Vaccinex Stock Wednesday? - Benzinga
Vaccinex secures $6.2 million through warrant exercises - Investing.com India
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds - GlobeNewswire
(VCNX) Investment Report - Stock Traders Daily
Vaccinex, Inc. (NASDAQ:VCNX) Sees Large Decline in Short Interest - Defense World
Vaccinex Director Chrystyna Bedrij Stecyk Abruptly Resigns - TipRanks
Vaccinex announces warrant cancellation option - Investing.com India
Vaccinex announces warrant cancellation option By Investing.com - Investing.com Canada
Vaccinex (VCNX) Extends Rally With New Clinical Insights - Stocks Telegraph
VCNX (Vaccinex) Short-Term Debt & Capital Lease Obligation : $0.18 Mil (As of Mar. 2024) - GuruFocus.com
VCNX (Vaccinex) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Mar. 2024) - GuruFocus.com
Vaccinex Inc Stock (VCNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):